摘要
目的:观察司库奇尤单抗联合窄谱中波紫外线治疗中重度银屑病患者的效果。方法:回顾性分析2022年3月至2023年3月该院收治的108例中重度银屑病患者的临床资料,按治疗方式不同分为观察组和对照组各54例。对照组采用窄谱中波紫外线局部照射治疗,观察组在对照组基础上采用司库奇尤单抗注射液治疗,比较两组治疗总有效率、银屑病面积与严重程度指数(PASI)评分、瘙痒视觉模拟评分法(VAS)评分、炎性指标[白细胞介素(IL)-2、IL-4、IL-10、干扰素-γ(INF-γ)]水平和不良反应发生率。结果:观察组治疗总有效率为92.59%,高于对照组的77.78%,差异有统计学意义(P<0.05);治疗后,两组PASI、VAS评分及血清IL-2、INF-γ水平低于治疗前,且观察组低于对照组,两组血清IL-4、IL-10水平高于治疗前,且观察组高于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:司库奇尤单抗联合窄谱中波紫外线治疗中重度银屑病患者可提高治疗总有效率,降低PASI、VAS评分,改善炎性指标水平,效果优于单纯窄谱中波紫外线治疗。
Objective:To observe effects of Secukinumab combined with narrow-band UVB in treatment of patients with moderate to severe psoriasis.Methods:The clinical data of 108 patients with moderate to severe psoriasis admitted to this hospital from March 2022 to March 2023 were retrospectively analyzed.According to different treatment methods,they were divided into observation group and control group,54 cases in each group.The control group was treated with narrow-band UVB local irradiation,while the observation group was treated with Secukinumab injection on the basis of that of the control group.The total effective rate of treatment,the psoriasis area and severity index(PASI)score,the pruritus visual analogue scale(VAS)score,the inflammatory factors[interleukin(IL)-2,IL-4,IL-10,interferon-γ(INF-γ)]levels,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 92.59%,which was higher than 77.78%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the PASI and VAS scores,and the serum IL-2 and INF-γlevels in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;the levels of serum IL-4 and IL-10 in the two groups were higher than those before the treatment,and those in the observation group were higher than those in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Secukinumab combined with narrow-band UVB in the treatment of the patients with moderate to severe psoriasis can improve the total effective rate of treatment,reduce the PASI levels and the VAS scores,and improve the levels of inflammatory factors.Moreover,it is superior to single narrow-band UVB treatment.
作者
常明明
CHANG Mingming(Department of Dermatology of Wugang People’s Hospital,Wugang 462500 Henan,China)
出处
《中国民康医学》
2024年第2期45-47,共3页
Medical Journal of Chinese People’s Health
